Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracic radiotherapy added to durvalumab plus chemotherapy in extensive-stage small-cell lung cancer
2021-001648-91Phase 3Active
- Sponsor
- Norwegian University of Science and Technology
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of durvalumab in small cell lung cancer (SCLC) (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: 1-year overall survival. Started Jun 2021; status: active.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2021-001648-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001648-91.